Due to that traditional chemotherapy drugs and targeted drugs have certain cardiac toxicity in breast cancer treatment, the combination application of anthracyclines and HER-2-targeted therapy seems to significantly increase vascular endothelial dysfunction compared with targeted therapy alone. The gene discussed is ERBB2; the disease is breast cancer.